Catalog No.
DHG32201
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Surface-expressed protease, Gelatine degradation protease FAP, Integral membrane serine protease, Dipeptidyl peptidase FAP, Seprase, FAP, Post-proline cleaving enzyme, APCE, SIMP, FAPalpha, 170 kDa melanoma membrane-bound gelatinase, Fibroblast activation protein alpha, Serine integral membrane protease, Prolyl endopeptidase FAP
Concentration
2.8mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q12884
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
BIBH1, CAS: 216669-97-5
Clone ID
Sibrotuzumab
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer, PMID: 12738716
Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer, PMID: 12624517
Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients, PMID: 14707493
Reprograming Carcinoma Associated Fibroblasts by microRNAs, PMID: 29210650
Tumors and their microenvironments: tilling the soil. Commentary re: A. M. Scott et al., A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res., 9: 1639-1647, 2003, PMID: 12738710
Gateways to clinical trials, PMID: 15071612
Fibroblast activation protein: A potential therapeutic target in cancer, PMID: 22236832
Molecular characterization of sarcomatous change in a granulosa cell tumor, PMID: 17316362
Near-infrared Photoimmunotherapy Targeting Cancer-Associated Fibroblasts in Patient-Derived Xenografts Using a Humanized Anti-Fibroblast Activation Protein Antibody., PMID:38638034
An antibody-radionuclide conjugate targets fibroblast activation protein for cancer therapy., PMID:37318538
Reprograming Carcinoma Associated Fibroblasts by microRNAs., PMID:29210650
Fibroblast activation protein: A potential therapeutic target in cancer., PMID:22236832
Molecular characterization of sarcomatous change in a granulosa cell tumor., PMID:17316362
Gateways to clinical trials., PMID:15071612
Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients., PMID:14707493
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer., PMID:12738716
Tumors and their microenvironments: tilling the soil. Commentary re: A. M. Scott et al., A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res., 9: 1639-1647, 2003., PMID:12738710
Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer., PMID:12624517
For research use only. Not for human or drug use.
